Table 4.
Summary of adverse events.
| Adverse event | Grade: number of patients | |||
|---|---|---|---|---|
| 1 | 2 | 3 | 4 | |
| Nonhematologic toxicity | ||||
| Fatigue | 55 | 16 | 5 | — |
| Proteinuria | 23 | 28 | — | — |
| Hypertension | 8 | 13 | 4 | 3 |
| Hypophonia | 12 | — | — | — |
| Hyperpigmentation | 5 | — | — | — |
| Hemorrhage, CNS | 5 | 2 | — | — |
| Hemorrhage, GI | — | 2 | — | — |
| Epistaxis | 4 | — | — | — |
| Stroke | 1 | 1 | 1 | — |
| DVT | — | 2 | 3 | — |
| PE | 3 | 1 | 1 | — |
| Wound dehiscence | 4 | 1 | 1 | — |
| Infection | 2 | — | — | — |
| Rash | — | — | — | — |
| GI perforation/fistula | — | — | — | — |
| Transaminase elevation | — | — | — | — |
| Hematologic toxicity | — | — | — | — |
| Anemia | 4 | 2 | 2 | — |
| Neutropenia | 5 | 6 | 18 | 3 |
| Thrombocytopenia | 9 | 17 | 14 | 2 |